SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerEvaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By SurgeryRadiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate CancerImatinib in Adult Patients With Metastatic Ocular MelanomaPhase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of GlioblastomaEvaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast CancerA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerLapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerObservation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members SarcomaDose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad PrognosisRadiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal CancerTo Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)FALCOn (Facteur AnthropoLogique Cancer Orl)A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBCCombination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic CancerTriptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate CancerHormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate CancerCapecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal CancerCombination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell TumorsImatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorHigh-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III MelanomaCombination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung CancerMEN-10755 in Treating Adults With Recurrent or Refractory Solid TumorsKRN7000 in Treating Patients With Solid TumorsMonoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic SyndromeMEN-10755 in Treating Patients With Solid TumorsBIBX 1382 in Treating Patients With Solid TumorsE7070 in Treating Patients With Solid TumorsNivolumab in Recurrent and/or Metastatic SCCHNA Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursAdjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine TreatmentProspective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall SurvivalPre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to FluoropyrimidinesFeasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotEvaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and NeckEfficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue LeiomyosarcomasA Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaResearch of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC PatientsEverolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
P6153
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of GlioblastomaObservation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members SarcomaDose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad PrognosisFALCOn (Facteur AnthropoLogique Cancer Orl)Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue SarcomaMonitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer ImmunotherapyProspective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall SurvivalFeasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotEvaluation of Pain and Postoperative Nausea Vomiting Incidence in Outpatient Surgery at IUCT-Oncopole HospitalProspective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma PatientsCohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).Optimization of the Patient Care Pathway in Immuno-oncologyChronic Pain and Minor Breast Cancer Surgery
P859
Q48092022-4E42D9A4-9BC5-42D7-93F7-B04EC069C275Q50859606-6E16B979-9419-4968-8E2A-01DB1BBA2D6BQ53001636-F9B7577E-2C43-492B-AD07-DF1909201D5CQ57419613-C0EB0003-6A0A-475F-A57A-E0A2CF4FEE44Q57617126-432308AE-F030-4A3D-993A-E0A052AE0C74Q58129229-EB2482F2-F894-47DD-870D-FAEB89F59132Q59671246-6F5F91F3-0B81-49EE-9857-0C83EBEB4004Q71853760-31347BC5-BA65-4A8D-89FF-83C05D70F618Q87969575-A959B6CC-E374-49EA-AAA5-C52701624920
P108
Q58407870-6D51B05C-28B0-4BD2-B0E4-82A40910F41EQ61908980-EC39169E-0716-466C-9971-025A1DE29B37Q61921622-18D29124-9759-4074-BC65-496E1444161CQ61921688-17FF8E90-5E04-4913-9E4D-6049C19F1CA2Q61921883-EDCCEA36-F777-4ADD-9463-28CB6496FCC2Q61956739-5E45BA43-DB3C-4A9B-9F35-636B5E32E93FQ61965724-BD94EC5A-B388-4A6D-9219-E91441C7366EQ61975530-5068A0EF-4339-4421-BA2D-4CC6525528A8Q61978988-A6B9855F-0EC0-40B7-9971-4B1CF2B1D7F6Q61980623-DBFD2C26-DBD7-4488-A01F-A64675267C94Q61981174-157A4FBA-AD11-466A-BB2C-63EC24E16973Q61981439-864DF22D-A677-410B-829D-89B4D0423CA4Q62025926-55F771FB-43C9-4DE9-B3CD-ACB0939B744AQ62062108-6154BCEB-A943-49C3-B7CA-A579DC95F760Q62062312-D3A65D47-CDD1-4388-8C8B-F67BC8058A7CQ62105033-6126C7B1-6A57-484B-8CFD-B5679347ACD5Q62105842-4FDA7A56-9689-4527-9803-A1596A0C15BDQ62105845-038880E3-F84C-4CE9-B8CB-6D76477646D8Q62105847-F1BE6150-D77E-4EFB-A502-A86ADC50D630Q62105848-3E7BA3C7-2E60-4766-A05A-07B60BEF6E1DQ62106097-BAFCCCD9-0E78-40E4-B182-CECBABB190FEQ62110345-86E9B6F5-1DE1-4761-A184-7DC9578A8C82Q62110649-7D29BB28-97A6-4D26-92A8-2FF15B0A7DFBQ62110664-95CE6DD3-8B71-49D5-B317-347E187ABA0EQ62110963-FD6A65FF-2A66-4865-BF8D-EC100AFC398CQ62110964-F4D35BF5-955E-4E6D-8810-F2887078DE36Q62110965-9AC93528-70A8-4313-A7C4-8A2BAA609848Q62110966-8D730651-79BB-4C05-8A45-91431BBD6E34Q62111017-B2EF0D82-BE05-438E-95A2-AAE9626A6534Q63013537-B4586A88-4515-4DD4-B1B3-250B0429BE94Q63315542-458023BF-B4D7-4E1C-9FC8-BA5A9F26160CQ63315910-98EDF72D-3FA8-42E5-8AC7-F09699534D03Q63316005-507C26AE-46DA-420F-8681-4206356069F4Q63316532-CF25D549-2C16-4084-A1BC-D8CFA48F3028Q63319104-E5C2EB25-49E8-4677-8BF7-1854EF289E92Q63320880-CF987D03-3C6C-4BD2-858C-F8A796151BB1Q63322121-263ED296-933E-40DE-9483-6EE80157DF9FQ63322572-84E39378-61E6-4D62-A147-5D3CAED9C779Q63322927-1C2FF6DC-33E3-4CD1-8768-4C064297E43DQ63336985-5B73F9A7-ADA2-4D4E-A32F-79696A851ABE
P6153
Q61902373-C8AD02E2-DB44-49FC-9CC7-AB764E544F9CQ61902815-581A8B47-97AB-4FC6-A361-34DD1D91DD52Q61956739-1358239C-8785-498F-9D8C-5B85A495B821Q61980623-CB293F03-0C7C-49CA-B1CE-09CD2EF91414Q61981174-C4E227AC-ED0F-4125-AA19-243EB4972335Q62062108-5FCAB2F0-ED3A-481E-9EE9-9CA903F656D0Q62818752-10EABD82-0577-4823-BB00-CC7BD0F4321AQ62818757-BDC5A792-0956-4CB1-B39D-C4F488A6F5F8Q63316005-37EF4F16-C65D-4D0B-A3A9-5157F3B8AE1CQ63319104-8328CBFB-CCBA-4E2D-99F4-15C0AC682811Q63392918-2DB2A1D0-45C3-429B-B42B-4C4D625F7A2DQ63393413-52373254-60E7-4928-B8B9-72B098DCEC68Q63393501-7DBEB4AE-A31D-433B-BF51-64DA1E54835FQ63401484-C7AD5AEA-7174-4727-8040-215E6A257E07Q63533936-0F9DE73E-3B3F-44BA-89FF-AEA5B3A40855Q63578803-DC090348-5B76-4730-91DD-BC3FD6C1FA3A
P859
description
Krankenhaus
@de
griya sakit
@jv
hospital de Francia
@ast
hospital in France
@en
rumah sakik
@min
rumah sakit di Prancis
@id
rumoh sakét
@ace
ziekenhuis in Toulouse, Frankrijk
@nl
בית חולים בצרפת
@he
مستشفى
@ar
name
Institut Claudius Regaud
@en
Institut Claudius-Regaud
@fr
type
label
Institut Claudius Regaud
@en
Institut Claudius-Regaud
@fr
altLabel
Centre Claudius Regaud
@fr
Institut Claudius Regaud
@fr
prefLabel
Institut Claudius Regaud
@en
Institut Claudius-Regaud
@fr
P214
P244
P268
P269
P3153
P131
P17
P213
0000 0000 9680 0846
P214
P2427
grid.417829.1
P244
n2016181440
P268
P269
P3153
501100008381
P3215
77692637000037
P3608
FR72776926370
P4058
P5785
P625
Point (1.431053 43.555464)
P6773
P6782
P7859
lccn-n2016181440